Developmental signaling pathways control a vast array of biological processes during
embryogenesis and in adult life. The WNT pathway was discovered simultaneously in …

Dual-energy X-ray absorptiometry (DXA) was the first imaging tool widely utilized by
clinicians to assess fracture risk, especially in postmenopausal women. The development of …

Romosozumab, a humanized monoclonal antibody that binds and inhibits sclerostin, has the
dual effect of increasing bone formation and decreasing bone resorption. As previously …

High-resolution peripheral computed tomography (HR-pQCT) was developed to image bone
microarchitecture in vivo at peripheral skeletal sites. Since the introduction of HR-pQCT in …

Osteoporosis represents the most common bone disease worldwide and results in a
significantly increased fracture risk. Extrinsic and intrinsic factors implicated in the …

Romosozumab is a bone‐forming agent with a dual effect of increasing bone formation and
decreasing bone resorption. In FRActure study in postmenopausal woMen with …

Osteoporosis is a metabolic bone disease with a high prevalence that affects the population
worldwide, particularly the elderly. It is often due to fractures associated with bone fragility …

This review focuses on new developments and current controversies in the field of
quantitative computed tomography. Recent positions of the International Society for Clinical …

Osteoporosis is characterized by reduced bone mass and disruption of bone architecture,
resulting in increased risk of fragility fractures and significant long-term disability. Although …

Introduction: Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the
canonical Wnt signaling bone formation pathway. Romosozumab is a humanized …